Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vemurafenib and Sorafenib in Advanced KRAS Mutated Pancreatic Cancer
NCT05068752Phase 2Completed
- Sponsor
- HonorHealth Research Institute
- Start
- Oct 2021
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vemurafenib, sorafenib in pancreatic cancer (PC), sponsored by HonorHealth Research Institute. Started Oct 2021; status: completed.
02
Drugs
vemurafenibsorafenib
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05068752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05068752.